Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

On: April 24, 2026, 10:19 am EDT

URL has been copied successfully!

Share this story:

Previous Post:BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models

Next Post:ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends